Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia

Fiona C Brown,Xin Wang,Richard W Birkinshaw,Chong Chyn Chua,Thomas David Morley,Sila Kasapgil,Giovanna Pomilio,Piers Blombery,David Ching Siang Huang,Peter E Czabotar,Salvatore F Priore,Guang Yang,Martin P. Carroll,Andrew H. Wei,Alexander E. Perl
DOI: https://doi.org/10.1182/bloodadvances.2024014446
IF: 7.642
2024-10-11
Blood Advances
Abstract:We report and characterize three venetoclax-resistant BCL2 variants arising during venetoclax/azacitidine therapy in acute myeloid leukemia (AML). Our results indicate the potential for on-target venetoclax resistance in patients with AML at relapse.
hematology
What problem does this paper attempt to address?